OmniAb, Inc. (OABI)
Market Cap | 191.75M |
Revenue (ttm) | 26.39M |
Net Income (ttm) | -62.03M |
Shares Out | 122.13M |
EPS (ttm) | -0.61 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 906,500 |
Open | 1.550 |
Previous Close | 1.530 |
Day's Range | 1.485 - 1.570 |
52-Week Range | 1.700 - 4.960 |
Beta | 0.92 |
Analysts | Strong Buy |
Price Target | 7.00 (+345.86%) |
Earnings Date | May 8, 2025 |
About OABI
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company’s technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners’ drug development efforts. Its OmniAb platform’s Biological Intelligence powers the immune systems of its proprietary and engineered transgenic anim... [Read more]
Financial Performance
In 2024, OmniAb's revenue was $26.39 million, a decrease of -22.75% compared to the previous year's $34.16 million. Losses were -$62.03 million, 22.5% more than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price forecast is $7.0, which is an increase of 345.86% from the latest price.
News

OmniAb Reports First Quarter 2025 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. “We hav...

OmniAb Introduces the xPloration® Partner Access Program
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today introduced the launch of the xPloration Partner Access Program, under which current OmniAb partners can purchase the xPloration i...

VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program
Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid Tumors Partnership Combines VERAXA's Proprietary ADC Technology...

OmniAb to Participate in Five Upcoming Investor Conferences
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in five investor conferences over the coming weeks. H.C. Wainwright 1st Annual Ro...

OmniAb Announces Two New Appointments to its Board of Directors
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the appointments of Philip J. Gotwals, Ph.D., and Steve Crouse to its Board of Directors. OmniAb also announced the dep...

OmniAb, Inc. (OABI) Q4 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Co...

OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2024, and provided operating and partner program update...

OmniAb to Report Fourth Quarter 2024 Financial Results on March 18
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and 12 months ended December 31, 2024 after the close of the U.S. financial markets on Tues...

OmniAb to Participate in Two Investor Conferences in March
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of March. TD Cowen 45th Annual Healt...

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of OmniAb, Inc. (NASDAQ: OABI) breached their fiduc...

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that two presentations featuring the Company's technologies were delivered at the 2024 Antibody Engineering & Therapeut...

OmniAb, Inc. (OABI) Q3 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer...

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program upd...

OmniAb to Participate in Two Investor Conferences in November
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of November. Stifel 2024 Healthcare ...

OmniAb to Report Third Quarter 2024 Financial Results on November 12
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and nine months ended September 30, 2024 after the close of the U.S. financial markets on T...

OmniAb to Participate in Two Investor Conferences in September
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating in two investor conferences during the month of September. H.C. Wainwright 26th A...

OmniAb, Inc. (OABI) Q2 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI) Q2 2024 Earnings Call August 8, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President and Chief Executive Officer Conference ...

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and six months ended June 30, 2024, and provided operating and partner program updates. ...

Long Assets On Path To Creating Significant Value, Shorting Remains Very Challenging
In the first half of 2024, our long book performed strong relative to the Russell 2000, driven by our high-conviction positions. We are pleased with our relative performance and believe the Russell 20...

OmniAb to Report Second Quarter 2024 Financial Results on August 8
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI) will report financial results for the three and six months ended June 30, 2024 after the close of the U.S. financial ma...

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced the publication of a peer-reviewed paper titled “Chickens with a Truncated Light Chain Transgene Express Single-Domain ...

OmniAb to Participate in the Jefferies Global Healthcare Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) today announced that management will be participating at the Jefferies Global Healthcare Conference, being held June 4-6, 2024 at the M...

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit
EMERYVILLE, Calif.--(BUSINESS WIRE)--OmniAb, Inc. (Nasdaq: OABI) today announced its participation in the 20th Annual PEGS Boston – The Essential Protein & Antibody Engineering Summit underway at the ...

OmniAb, Inc. (OABI) Q1 2024 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Kurt Gustafson - Chief Financial Officer Matt Foehr - President & Chief Executive Officer Confe...

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights
EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #Antibody--OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner prog...